MiniMed Group reported $843 million in sales for the three months ended July 31, 2026, with Net Income at $0 and diluted EPS at $0.00. Cash and cash equivalents totaled $207 million, while the company had access to a $500 million revolving Credit Facility with no amounts outstanding.

Key Highlights

  • Gross profit reached $465 million, compared with $409 million in the comparable period.
  • Operating income was $5 million, versus an Operating Expense of $13 million previously.
  • Cash and cash equivalents stood at $207 million, alongside a $500 million undrawn revolving credit facility.

Net income attributable to the company was $0, while Diluted Earnings per Share was $0.00.

Quarterly Profit Measures

Gross profit reached $465,000,000 ($465 million), compared with $409,000,000 ($409 million) in the comparable period. Cost of products sold was $378,000,000 ($378 million), versus $314,000,000 ($314 million). Research and Development expense was $115,000,000 ($115 million), down from $125,000,000 ($125 million). Selling, general, and administrative expense was $312,000,000 ($312 million), compared with $283,000,000 ($283 million). Certain litigation charges, net, were a $2,000,000 ($2 million) Reversal for the quarter, compared with a $17,000,000 ($17 million) charge in the comparable period. Other operating expense, net, was $36,000,000 ($36 million), compared with other operating income, net, of $2,000,000 ($2 million). Operating Income was $5,000,000 ($5 million), compared with an operating expense of $13,000,000 ($13 million). Income before income taxes was $4,000,000 ($4 million), compared with a pretax loss of $13,000,000 ($13 million). The income tax provision was $4,000,000 ($4 million), compared with $3,000,000 ($3 million).

Earnings Per Share And Equity

Net income was $0, compared with a net loss of $16,000,000 ($16 million) in the comparable period. Net income attributable to noncontrolling interests was $0, compared with a loss attributable to noncontrolling interests of $3,000,000 ($3 million). Net income attributable to MiniMed Group (NASDAQ: MMED) was $0, compared with a loss of $19,000,000 ($19 million). Basic and diluted weighted-average shares outstanding were 281.0 million, compared with 252.8 million. The company’s comprehensive loss was $2,000,000 ($2 million), compared with $5,000,000 ($5 million) in the comparable period. The current-period result included a translation adjustment loss of $2,000,000 ($2 million), while the comparable period included a translation adjustment gain of $11,000,000 ($11 million).

Cash And Credit Availability

Cash and cash equivalents totaled $207,000,000 ($207 million) at July 31, 2026, compared with $298,000,000 ($298 million) at April 24, 2026. Accounts receivable, net of allowances for credit losses, stood at $180,000,000 ($180 million), compared with $200,000,000 ($200 million). No amounts were outstanding under the facility at July 31, 2026, and the company was in compliance with its applicable covenants.

Operating Cash Flow

Operating activities used $49,000,000 ($49 million) during the quarter, compared with $141,000,000 ($141 million) used in the comparable period. Investing activities used $41,000,000 ($41 million), compared with $63,000,000 ($63 million). Financing activities produced neither cash inflow nor cash outflow in the current period, compared with $202,000,000 ($202 million) provided in the comparable period. Exchange-rate effects reduced cash and cash equivalents by $1,000,000 ($1 million), compared with no effect in the comparable period.